GGrantIndex
← Search

COG NCTN Network Group Operations Center

$229,232U10FY2014CANIH

Children'S Hosp Of Philadelphia, Philadelphia PA

Investigators

Linked publications, trials & patents

Trial NCT07621614Trial NCT07466316Trial NCT07437963Trial NCT07072585Trial NCT06820957Trial NCT06647953Trial NCT06401330Trial NCT06368817Trial NCT06317662Trial NCT06172296Trial NCT06124157Trial NCT06064097Trial NCT05828069Trial NCT05761171Trial NCT05691478Trial NCT05675410Trial NCT05504291Trial NCT05457556Trial NCT05382338Trial NCT05320380Trial NCT05304585Trial NCT05287295Trial NCT05235165Trial NCT05099003Trial NCT04994132Trial NCT04759586Trial NCT04726241Trial NCT04684368Trial NCT04576117Trial NCT04546399Trial NCT04385277Trial NCT04322318Trial NCT04320888Trial NCT04293562Trial NCT04284774Trial NCT04203316Trial NCT04195555Trial NCT04195399Trial NCT04166409Trial NCT03959085Trial NCT03919071Trial NCT03914625Trial NCT03871257Trial NCT03834961Trial NCT03817398Trial NCT03794349Trial NCT03786783Trial NCT03698994Trial NCT03595124Trial NCT03581292Trial NCT03533582Trial NCT03526250Trial NCT03233204Trial NCT03220035Trial NCT03213704Trial NCT03213691Trial NCT03213678Trial NCT03213665Trial NCT03213652Trial NCT03210714Trial NCT03190915Trial NCT03155620Trial NCT03126916Trial NCT03067181Trial NCT03007147Trial NCT02981628Trial NCT02900976Trial NCT02883049Trial NCT02867592Trial NCT02828358Trial NCT02724579Trial NCT02642965Trial NCT02567435Trial NCT02521493Trial NCT02487979Trial NCT02484443Trial NCT02470091Trial NCT02452554Trial NCT02339740Trial NCT02306161Trial NCT02180867Trial NCT02176967Trial NCT02166463Trial NCT02112916Trial NCT02101853Trial NCT02097238Trial NCT02097134Trial NCT02017964Trial NCT01979536Trial NCT01824693Trial NCT01798004Trial NCT01780662Trial NCT01767194Trial NCT01602666Trial NCT01553149Trial NCT01371981Trial NCT01236560Trial NCT01231906Trial NCT01217437Trial NCT01190930

Abstract

DESCRIPTION (provided by applicant): Since the introduction of chemotherapy for the treatment of childhood leukemia more than sixty years ago, the, prognosis for children with cancer has improved dramatically. The 5-year survival rate for childhood cancers, many of which were uniformly fatal in the pre-chemotherapy era, is now approaching.80%. Despite these advances, several childhood cancers still have unacceptably low cure rates, and even when treatment is successful, the acute and long-term morbidity of current therapy can be substantial. The Children's Oncology Group (COG), the world's largest organization devoted exclusively to childhood and adolescent cancer research, was founded 12 years ago. The COG's multidisciplinary research team, comprised of more than 8,000 members, conducts research at more than 200 leading children's hospitals, universities, and cancer centers. This proposal is for COG, as part of NCI's new National Clinical Trials Network, to continue its collaborative research work that supports the mission of improving the outcome for all children with cancer. The COG will design and conduct clinical-translational studies for children with cancer that builds on an increasing understanding of the molecular basis for pediatric malignancies and has the highest potential to improve the outcome. Using innovative clinical trial designs suitable for the study of rare diseases, we will study novel therapeutic approaches that range from targeted, small molecules to cellular therapies. As more than 90% of children diagnosed with cancer in the US are treated at COG member institutions, the COG has the ability to offer to children with cancer and their families to participation in research that allows for collection and annotation of biospecimens from all children with cancer, providing the foundation for discovery and accelerating the most promising research efforts conducted in laboratories around the world. The COG research portfolio importantly also includes research trials focused on improving the quality of life children with cancer and survivors. The proposal is for support of the COG Group Operations Center, clinician-scientists who develop and conduct research, and for member sites to participate through enrollment of eligible subjects.

View original record on NIH RePORTER →